Elevance Health (ELV) CAO sells 369 shares in open-market trade

Q: At what price did the Elevance Health (ELV) insider sell shares?

The insider’s weighted average sale price was $403.16 per share , with individual trades executed between $403.15 and $403.31 . The filing notes the full trade breakdown is available to the SEC, the issuer, or any security holder upon request.

Q: How many Elevance Health (ELV) shares does the insider hold after the sale?

After selling 369 shares, Ronald W. Penczek directly holds 3,740 shares of Elevance Health common stock. This post-transaction ownership figure is explicitly reported to give investors context on his remaining equity position in the company.

Q: Who is the Elevance Health (ELV) insider involved in this Form 4 filing?

The reporting person is Ronald W. Penczek , who serves as Chief Accounting Officer and Controller of Elevance Health. The filing indicates the sold and remaining shares are held as direct ownership in the company’s common stock.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Elevance Health, Inc. Chief Accounting Officer and Controller Ronald W. Penczek reported an open-market sale of 369 shares of common stock. The weighted average sale price was $403.16 per share, with individual trades priced between $403.15 and $403.31. Following this transaction, he directly owns 3,740 shares.

Insider Trade Summary

Net Seller: 369 shares ($148,766)

Net Sell 1 txn

Insider Penczek Ronald W

Role CAO & Controller

Sold 369 shs ($149K)

Type	Security	Shares	Price	Value
Sale	Common Stock	369	$403.16	$149K

Holdings After Transaction: Common Stock — 3,740 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 369 shares Sale price (weighted average): $403.16 per share Price range of trades: $403.15–$403.31 per share +1 more

4 metrics

Shares sold 369 shares Open-market sale on June 12, 2026

Sale price (weighted average) $403.16 per share Common stock open-market sale

Price range of trades $403.15–$403.31 per share Multiple trades within one transaction

Shares owned after transaction 3,740 shares Direct holdings after sale

Key Terms

open-market sale, weighted average sale price, Form 4

3 terms

open-market sale financial

"reported an open-market sale of 369 shares of common stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"The price reported reflects the weighted average sale price"

Form 4 regulatory

"This transaction is reported on a Form 4 insider trading report"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/15/2026 - 04:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Penczek Ronald W

(Last)

(First)

(Middle)

220 VIRGINIA AVENUE

(Street)

INDIANAPOLIS

INDIANA

46204

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Elevance Health, Inc. [ ELV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CAO & Controller

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/12/2026		S		369	D	$403.16⁽¹⁾	3,740	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $403.15 to $403.31. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Kathleen S. Kiefer, Attorney in fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Elevance Health (ELV) report in this Form 4?

Elevance Health reported that executive Ronald W. Penczek completed an open-market sale of 369 shares of common stock. The transaction is disclosed as a routine Form 4 insider trading report for regulatory transparency and shareholder awareness.

At what price did the Elevance Health (ELV) insider sell shares?

The insider’s weighted average sale price was $403.16 per share, with individual trades executed between $403.15 and $403.31. The filing notes the full trade breakdown is available to the SEC, the issuer, or any security holder upon request.

How many Elevance Health (ELV) shares does the insider hold after the sale?

After selling 369 shares, Ronald W. Penczek directly holds 3,740 shares of Elevance Health common stock. This post-transaction ownership figure is explicitly reported to give investors context on his remaining equity position in the company.

Was the Elevance Health (ELV) insider sale executed in a single trade?

No. The Form 4 states the sale was executed in multiple trades within a narrow price range of $403.15 to $403.31. The reported $403.16 price represents the weighted average across those individual trades for disclosure purposes.

Who is the Elevance Health (ELV) insider involved in this Form 4 filing?

The reporting person is Ronald W. Penczek, who serves as Chief Accounting Officer and Controller of Elevance Health. The filing indicates the sold and remaining shares are held as direct ownership in the company’s common stock.